ClinicalTrials.gg
Not yet recruitingNCT07192484Updated Sep 25, 2025

Effects of Kinesio Taping in Subacute Stroke Patients

An interventional study of KT group and Conventional group in Stroke Gait Rehabilitation, sponsored by Fooyin University. Not yet recruiting. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-25.

Sponsored by Fooyin University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

A study was designed to investigate the effects of KT on gait ability, balance, and neuromuscular functions in subacute stroke patients with foot drop. The study aims to evaluate the immediate and short-term effects of KT on gait ability, balance, and neuromuscular function in subacute stroke patients with foot drop. A total of 60 participants will be recruited and randomly assigned to either a control group (conventional physical therapy) or an experimental group (receiving additional KT). Both groups will receive 30 minutes of daily physical therapy. The experimental group will undergo an initial assessment before KT application, which includes (1) activation of the dorsiflexor muscles, (2) reduction of plantar flexor spasticity, and (3) stabilization of the ankle in an everted position. After taping, a second assessment will be conducted immediately, and the tape will stay applied to patient's limb for two days, followed by a third assessment. The control group will be assessed only before the intervention and after two days. Primary outcome measures include gait ability (10-meter walk test, laboratory gait parameters, and joint angles and electromyographic activity during walking). Secondary outcomes include balance (Functional reach test, Timed Up and Go test, and Activities-specific Balance Confidence Scale) and neuromuscular function assessments (muscle strength, joint range of motion, spasticity, and proprioception). This project aims to establish and validate a clinically applicable and effective KT protocol as an adjunctive gait training method for subacute stroke patients with foot drop. By enhancing independent and safe walking, this intervention may facilitate the early return to normal daily activities for stroke survivors.

02

Conditions studied

  • Stroke Gait Rehabilitation

Browse trials for

03

In context

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

This study's planned enrollment of 60 is above the median of 48 across 6,049 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

Fooyin University is the lead sponsor of 18 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 20 and 80 years;
  • First unilateral stroke;
  • Stroke onset between at least 1 week and 1 year;
  • Ability to continuously walk 10 meters with or without assistive devices;
  • Presence of foot drop on the affected side during the swing phase due to insufficient ankle dorsiflexion;
  • Brunnstrom stage of the affected lower limb ≥ 3;
  • Presence of mild spasticity in the affected ankle plantar flexors, with a Modified Ashworth Scale score ≤ 2;
  • Ability to follow simple commands

Exclusion criteria

Exclusion Criteria:

  • Other neurological disorders or unstable medical conditions;
  • Skin allergies that interfere with the use of tape;
  • Visual field defects;
  • Cognitive impairment, defined as a (MMSE) score \< 24;
  • Pusher syndrome;
  • Ankle contracture;
  • Hemispatial neglect;
  • Poorly controlled hypertension or cardiovascular disease;
  • Any other disease, apart from stroke, that may affect balance or gait.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    KT group

    Receiving additional Kinesio taping

    Behavioral: KT group

  • Other
    Control group

    Conventional physical therapy

    Behavioral: Conventional group

Interventions

  • BehavioralKT group

    Receiving additional KT

  • BehavioralConventional group

    Conventional physical therapy

06

What researchers measure

Primary outcomes

  1. Gait ability - 10 meter walk test

    The participant will be asked to walk at a comfortable speed along a 14-meter walkway. The examiner uses a stopwatch to record the time taken to walk the middle 10 meters, and then divides the distance (10 meters) by the time to calculate the walking speed.

    Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)

  2. Gait ability - Speed (m/s)

    The participant will be asked to walk at a comfortable speed along a 14-meter walkway. Speed (m/s) will be recorded using the commercially available portable gait analysis system (Gait Up).

    Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)

  3. Gait ability - Cadence (steps/minute)

    The participant will be asked to walk at a comfortable speed along a 14-meter walkway. Cadence (steps/minute) will be recorded using the commercially available portable gait analysis system (Gait Up).

    Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)

  4. Gait ability - Stride length (m)

    The participant will be asked to walk at a comfortable speed along a 14-meter walkway. Stride length (m) will be recorded using the commercially available portable gait analysis system (Gait Up).

    Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)

  5. Gait ability - Step length (m)

    The participant will be asked to walk at a comfortable speed along a 14-meter walkway. Step length (m) will be recorded using the commercially available portable gait analysis system (Gait Up).

    Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)

  6. Gait ability - Percentages of stance phase (%)

    The participant will be asked to walk at a comfortable speed along a 14-meter walkway. Percentages of stance phase (%) will be recorded using the commercially available portable gait analysis system (Gait Up)

    Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)

  7. Gait ability - Percentages of swing phase (%)

    The participant will be asked to walk at a comfortable speed along a 14-meter walkway. Percentages of swing phase (%) will be recorded using the commercially available portable gait analysis system (Gait Up).

    Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)

  8. Gait ability - Gait symmetry (%)

    Gait symmetry (%) will be recorded using the commercially available portable gait analysis system (Gait Up).

    Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)

  9. Gait ability - first maximum toe clearance (cm)

    The participant will be asked to walk at a comfortable speed along a 14-meter walkway. The first maximum toe clearance (cm) will be recorded using the commercially available portable gait analysis system (Gait Up).

    Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)

  10. Gait ability - second maximum toe clearance (cm)

    The participant will be asked to walk at a comfortable speed along a 14-meter walkway. The second maximum toe clearance (cm) will be recorded using the commercially available portable gait analysis system (Gait Up).

    Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)

  11. Gait ability - minimum toe clearance (cm)

    The participant will be asked to walk at a comfortable speed along a 14-meter walkway. The minimum toe clearance (cm) will be recorded using the commercially available portable gait analysis system (Gait Up).

    Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)

  12. Ankle joint range (degrees) during walking

    The participant will be asked to walk at a comfortable speed along a 14-meter walkway. Ankle joint range (degrees) during walking will be recorded using the commercially wireless system (Delsys Inc., United States).

    Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)

  13. EMG activity (µV) of tibialis anterior during walking

    The participant will be asked to walk at a comfortable speed along a 14-meter walkway. EMG activity (µV) of tibialis anterior during walking will be recorded using the commercially wireless system (Delsys Inc., United States).

    Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)

  14. EMG activity (µV) of gastrocnemius during walking

    The participant will be asked to walk at a comfortable speed along a 14-meter walkway. EMG activity (µV) of gastrocnemius during walking will be recorded using the commercially wireless system (Delsys Inc., United States).

    Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)

Secondary outcomes

  1. Functional reach test

    Participant is asked to stand by the wall without leaning against it, with hands clenched into fists and arms raised forward to shoulder height with the shoulder joints flexed at 90 degrees. The examiner records the position of the participant's third metacarpal bone as the starting point. Then, while keeping both arms raised, the participant is instructed to lean the body forward as far as possible. The examiner records the farthest position of the third metacarpal bone as the endpoint. The test result is determined by subtracting the starting point from the endpoint.

    Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)

  2. Timed Up and Go test

    In this test, a distance of three meters is marked on the floor, with a chair equipped with armrests and a backrest placed at one end. The participant is first asked to sit on the chair with their back against the backrest. When the examiner gives the start signal, the participant is required to rise from the chair, walk forward three meters at their usual walking speed to the marked line, turn around, walk back, and sit down on the chair again. The time taken from the moment the examiner gives the start signal until the participant has seated themselves back on the chair is recorded using a stopwatch.

    Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)

  3. Activities-specific Balance Confidence Scale

    This scale is a questionnaire designed to assess the participant's self-confidence in maintaining balance and avoiding falls in 16 situations that may be encountered in the community. Each of the 16 items is scored starting from 0, where 0 indicates no confidence at all. Scores are given in increments of 10, up to a maximum of 100, with 100 representing complete confidence.

    Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)

  4. Muscle strength

    Muscle strength of the ankle dorsiflexors will be measured using a handheld dynamometer (MicroFET3; Hoggan Health Industries, Salt Lake City, UT, USA). The participant lies supine on a treatment table with both feet hanging over the edge. The dynamometer is positioned on the dorsal aspect of the metatarsophalangeal joints to assess dorsiflexor strength. During the test, the examiner holds the dynamometer stationary while the participant exerts maximal force against it. Each contraction is sustained for 5 seconds, repeated three times, with a 10-second rest interval between trials. The mean value of the peak force obtained across the three trials will be used for analysis.

    Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)

  5. Joint range of motion

    Active range of motion (ROM) of ankle dorsiflexion and plantarflexion will be measured using a goniometer. The participant is positioned in a high sitting posture. The fulcrum of the goniometer is placed over the lateral malleolus of the ankle, with the stationary arm aligned parallel to the lateral aspect of the fibula and the moving arm aligned parallel to the fifth metatarsal. Starting from the neutral position at 0°, the participant is instructed to perform maximal active dorsiflexion followed by plantarflexion.

    Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)

  6. Spasticity

    The degree of ankle muscle spasticity will be assessed using the Modified Ashworth Scale (MAS). During the test, the joint is passively moved through its range of motion with a quick stretch to determine the presence of resistance. The scale consists of six grades (0, 1, 1+, 2, 3, 4), where a score of 0 indicates normal muscle tone and higher scores represent increasing severity of spasticity.

    Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)

  7. Proprioception

    Proprioception will be assessed using the inclinometer function of the muscle strength and angle measurement device (MicroFET3; Hoggan Health Industries, Salt Lake City, UT, USA) on the affected foot. The participant is seated on a treatment table with eyes closed and the knee extended, with the ankle positioned at 0° dorsiflexion as the starting position. The inclinometer is placed on the dorsum of the foot. The examiner passively positions the ankle to a target dorsiflexion or plantarflexion angle, and the participant is instructed to maintain this position for 10 seconds before returning to the starting position. The participant is then asked to actively reproduce the target angle. Both the examiner-set angle and the participant-reproduced angle are recorded, and the error between the two values is used to represent proprioceptive acuity.

    Time frame: 1. Baseline (prior to KT application, Day 1) 2. Immediately after KT application (Day 1) 3. 48 hours after KT application (Day 3)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Dec 2026, 15 months later.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 15 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2025
First posted
Sep 25, 2025
StartEst.
Sep 15, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07192484
Lead sponsor
Fooyin University
Responsible party
Sponsor
First posted
Sep 25, 2025
Start date
Sep 15, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 25, 2025

Study contacts

I-Hsuan Chen
Contact
Y0894@fy.edu.tw
886-7-7811151 #7043

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion